Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Trea
Nasal Administration of Dexamethasone for MS Treatment
What it found
The trial ended early for another reason (see below).
Reason given: was not approved by the ministry of health
What was tested
Treatment tested
- Dexamethasone soduim phosphate
What it measured
Main measures
reduction in the EDSS functional system score
four months
Disability progression
Who could take part
Relapsing MS · 18 and over
Show the full criteria
Inclusion criteria
* MS patients with esatblished relapsing remitting attacks * increase in EDSS of at least 1 point for a least one day
Exclusion criteria
* children under 18 * pregnant patients * patients with diabetes * known allergy to steroids * patients who received steroids within 3 months prior to the study
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The study aims to assess the safety and efficacy of nasale administration of Dexamethasone in relapsing MS patients
Papers
Loading reviews and guidelines…
Related trials
- Improving the Treatment of Acute Relapses in Multiple Sclerosis Throug
Phase 2 · Enrolling by invitation
Still running
- Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in
Phase 2 · Completed
No results found
- Methylprednisolone During the Switch Between Natalizumab and Fingolimo
Phase 4 · Status unknown
No results found
- Maximizing Outcome of Multiple Sclerosis Transplantation
Phase 3 · Stopped early
Stopped
- A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab
Phase 3 · Stopped early
Stopped
- Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse
Phase 4 · Stopped early
Stopped: safety
History
Started
Jul 2008
Main results due
Dec 2008
Finished
Jan 2009